Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab

Core Insights - Summit Therapeutics Inc. is advancing the development of ivonescimab for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) through multiregional Phase III clinical trials [1][2] Company Developments - The company has partnered with GORTEC to activate clinical sites for a Phase III study evaluating ivonescimab monotherapy and its combination with ligufalimab [2] - The US FDA has accepted the Biologics License Application (BLA) for ivonescimab in combination with chemotherapy [3] - Summit has also partnered with GSK plc to assess ivonescimab in combination with B7-H3 and risvutatug rezetecan across multiple solid tumors [3] Financial Performance - As of the end of Q4 2025, the company reported $713.4 million in cash and cash equivalents and $412.3 million in short-term investments [4] - The net loss for the full year 2025 increased to $347.2 million, or $0.46 per share, compared to a loss of $179.3 million, or $0.24 per share, in 2024 [4] Company Overview - Summit Therapeutics is a Miami-based biopharmaceutical company focused on oncology therapies aimed at improving patient quality of life and addressing unmet medical needs, with ivonescimab as its lead candidate targeting PD-1 and VEGF for solid tumors [5]